Interferon-β (IFN-β) is a mainstay therapy for multiple sclerosis. However, only two thirds of patients respond to therapy, and clinical symptoms worsen in some patients. Chandar Raman and his colleagues show that IFN-β alleviates disease induced by T helper type 1 cells and exacerbates disease induced by T helper type 17 cells in mice. They also show that these effects of IFN-β rely on IFN-γ signaling (pages 376–377).
- Robert C Axtell
- Brigit A de Jong
- Chander Raman
